Prepulse inhibition (PPI) of the startle reflex is an operational measure of sensorimotor gating that is deficient in several brain disorders and is disrupted in rats by dopamine (DA) agonists. Robust heritable strain differences are observed between Sprague-Dawley (SD) and Long-Evans (LE) strains in sensitivity to the PPI-disruptive effects of DA agonists associated with differential gene expression in the nucleus accumbens. Here, we compared the contribution of D2 versus D3 receptors with this heritable difference, using the D3-preferential agonist (pramipexole), the mixed D3/D2 agonist (quinpirole), the mixed D1/D2-like agonist (apomorphine), and the preferential D2 antagonist (L741,626). All DA agonists disrupted PPI in SD and LE rats. Greater sensitivity for this effect was evident with apomorphine and quinpirole in SD than LE rats, but not with pramipexole. The selective D2 antagonist L741,626 preferentially reversed apomorphine-induced PPI deficits at a dose that did not alter pramipexole-induced PPI deficits. We conclude that the heritable pattern of greater PPI 'disruptability' by DA agonists in SD versus LE rats reflects differences in D2 but not D3 receptorassociated mechanisms.
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Introduction
Evidence suggests that vulnerability for developing schizophrenia can be inherited (Harrison and Weinberger, 2005; Sullivan, 2005) and that genes conferring this vulnerability ultimately do so through changes in brain circuitry. Great effort is being put toward identifying the genetic basis of this vulnerability through the use of endophenotypes, that is, phenotypes that are intermediate between the genes and the more complex clinical manifestations of these diseases (Gottesman and Gould, 2003; Turetsky et al., 2007) . One useful schizophrenia endophenotype may be reduced prepulse inhibition (PPI) of the startle reflex (Graham, 1975) . Normal PPI of startle is a cross-species phenomenon that also occurs in humans, rats, and mice when a weak lead stimulus inhibits the response to an intense, abrupt startling stimulus. PPI is reduced in schizophrenia patients and their unaffected first-degree relatives (Braff et al., 1978 Cadenhead et al., 2000; Kumari et al., 2005) suggesting that deficient PPI may be a useful endophenotype for inherited forms of schizophrenia.
In rats, PPI is potently disrupted by dopamine (DA) receptor agonists, including the mixed D1/D2-like agonist, apomorphine (APO) and the mixed D3/D2 agonist, quinpirole (QUIN; Swerdlow et al., 1986; Mansbach et al., 1988 , Peng et al., 1990 cf Geyer et al., 2001) . Sensitivity to these PPI-disruptive effects of some DA agonists differs across the rat strains. For example, Sprague-Dawley (SD) rats from Harlan Laboratories (Livermore, California, USA) are significantly more sensitive to the PPIdisruptive effects of APO, QUIN, and the indirect DA agonist amphetamine, compared with Long-Evans (LE) rats from Harlan Laboratories (Swerdlow et al., 2001b (Swerdlow et al., , 2003 (Swerdlow et al., , 2004a Weber and Swerdlow, 2008) . These differences are innate (Swerdlow et al., 2004a, c) , neurochemically specific (Swerdlow et al., 2003 (Swerdlow et al., , 2004b , independent of stimulus modality (Weber and Swerdlow, 2008) and cannot be explained by differences in maternal behavior (Swerdlow et al., 2004a) . Finally, these strain differences seem to be linked to inherited properties of DA-linked G-protein function , and to differential nucleus accumbens (NAC) gene expression, particularly, among genes associated with DA-signaling pathways (Shilling et al., 2008) . Conceivably, this heritable strain difference in the 'disruptability' of PPI by DA activation may provide a useful model for understanding the basis for reduced PPI in heritable, DAlinked brain disorders such as, schizophrenia (Braff et al., 1978) and Tourette syndrome (Castellanos et al., 1996) .
Although existing data suggest a role of D2-family receptors in this model, we do not know which D2 receptor subtype (D2, D3, or D4) is responsible for the inherited phenotype of PPI 'disruptability'. Hence, in this study, we tested whether SD versus LE rats differed in sensitivity to the PPI-disruptive effects of the preferential D3 agonist pramipexole (PRA), in addition to the mixed D3/D2 agonist QUIN, and the mixed D1/D2-like agonist APO. To parse the potential contribution of D2 receptors to the PPI-disruptive effects of APO and PRA, these effects were also tested after pretreatment with the preferential D2 receptor antagonist L741,626 in SD rats.
Methods

Subjects
Adult male SD (n = 102) and LE (n = 38) rats (225-250 g; Harlan Laboratories) were housed in groups of two to three animals per cage, and maintained on a reversed light/dark schedule with water and food freely available. Rats were handled within 2 days of arrival. Testing occurred during the dark phase. All experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80-23) and were approved by the UCSD Animal Subjects Committee (protocol #S01221).
Apparatus
Startle chambers for rats (San Diego Instruments, San Diego, California, USA) were housed in a sound-attenuated room, and consisted of a Plexiglas cylinder 8.2 cm in diameter resting on a 12.5 Â25.5-cm Plexiglas frame within a ventilated enclosure. Noise bursts were presented through a speaker mounted 24 cm above the cylinder. A piezoelectric accelerometer mounted below the Plexiglas frame detected and transduced motion from within the cylinder. Stimulus delivery was controlled by the SR-LAB microcomputer and interface assembly, which also digitized (0-4095), rectified, and recorded stabilimeter readings. One hundred 1-ms readings were collected beginning at the time of stimulus onset. Startle amplitude was defined as the average of the 100 readings.
Startle testing procedure
Approximately 7 days after shipment arrival, rats were exposed to a short 'matching' startle session. They were placed in the startle chambers for a 5-min acclimation period with a 70 dB(A) background noise, and then exposed to a total of 17 P-ALONE trails [40 ms-120-dB(A) noise bursts] that were interspersed with three PP12dB + P-ALONE trials [P-ALONE preceded 100 ms (onset-to-onset) by a 20-ms noise burst of 12 dB above background]. Rats were assigned to drug dose groups based on average percentage of PPI from the matching session, to ensure similar baseline PPI levels between groups. The number of groups created in the matching session equaled the number of dose groups per strain. Average PPI in these groups was 55% for SD rats and 57% for LE rats. For each experiment and strain, average percentage of PPI of the dose groups typically differed by less than 3%. Group sizes ranged from 2 to 4 rats/strain/dose group/experimental day. All DA agonist studies (APO, PRA, and QUIN) used within-subjects, balanced dose order designs. The number of injections administered to each rat -and the number of experimental days needed to complete the experimentequaled the number of doses of the DA agonist (including vehicle treatment) tested. The sequence of drug doses administered was counterbalanced between animals to control for any effects of treatment day or sequence. Tests of L741,626 against APO or PRA were two-day studies and had a mixed model, balanced dose-order design with L741,626 as the between-subjects factor and APO or PRA as the within-subjects factor. Intertest intervals were 3-5 days for PRA and APO agonist studies, and 6-7 days when PRA and APO were tested against L741,626. Intertest interval was 11 days for QUIN, to minimize the known long-term effects of QUIN on D2 function and PPI (Culm and Hammer, 2004) .
Starting 4 days after the matching session, the effects of PRA were studied in two separate groups of rats. One group of rats received a low dose (range 0, 0.03, and 0.06 mg/kg), and another group of rats received a higher dose (range 0, 0.1, and 1.0 mg/kg). Each of these PRA experiments was followed by an APO experiment, beginning 4 days after the final injection of the PRA experiment using the same rats. For the APO experiment, rats were treated for 2 days with either vehicle or 0.5 mg/kg of APO. A separate group of rats was tested for 2 days, with either vehicle or 0.5 mg/kg of QUIN. Three experiments with L741,626 were conducted. First, PPI was tested after pretreatment with L741,626 (0, 1, 3, and 10 mg/kg) and treatment with APO (0 vs. 0.5 mg/kg). Second, in separate rats, PPI was tested after pretreatment with L741,626 (0 or 1 mg/kg) and treatment with a low dose of APO (0 vs. 0.1 mg/kg). Third, in separate rats, PPI was tested after pretreatment with L741,626 (0, 1, 3, or 10 mg/kg) and treatment with PRA (0 vs. 1.0 mg/kg). Pretreatment time for L741,626 relative to APO or PRA treatment was 30 min.
Immediately (APO), 10 min (QUIN), or 30 min (PRA) after injection of the DA agonists, rats were placed in the startle chambers for a 5-min acclimation period with a 70-dB(A) background noise. They were then exposed to a series of trial types, which were presented in pseudorandom order: (1) P-ALONE ALONE (a 40ms, 120-dB(A) noise burst); (2-4) P-ALONE preceded 100 ms (onset-to-onset) by a 20-ms noise burst of either 5 dB (PP5dB + P-ALONE), 10 dB (PP10dB + P-ALONE), or 15 dB above background (PP15dB + P-ALONE). Interspersed between these trials were trials in which no stimulus was presented, but cage displacement was measured (NOSTIM trials). The session began with four consecutive P-ALONE trials and ended with three consecutive P-ALONE trials; between these trials were two blocks, each consisting of eight P-ALONE trials, five PP5dB + P-ALONE trials, five PP10dB + P-ALONE trials, and five PP15dB + P-ALONE trials. Intertrial intervals were variable with an average length of 15 s. NOSTIM trials were not included in the calculation of intertrial intervals. Total session duration was 18.25 min.
Drugs
Apomorphine hydrochloride hemihydrate, quinpirole hydrochloride, 85% (w/v) lactic acid solution, and 1N NaOH solution were purchased from Sigma-Aldrich (St Louis, Missouri, USA). Pramipexole was purchased from Toronto Research Chemicals (North York, Ontario, Canada), and L741,626 was purchased from Tocris (Ellisville, Missouri, USA). Drug doses are based on milligram/kilogram of salts. All drugs were administered subcutaneously in a volume of 1 ml/kg. On the basis of pilot studies, PRA (saline vehicle 0.03, 0.06, 0.1, or 1.0 mg/kg) was administered 30 min before PPI testing, QUIN (saline vehicle or 0.5 mg/kg) was administered 10 min before PPI testing, and APO (0.01% ascorbate/ saline vehicle, 0.1 or 0.5 mg/kg) was administered immediately before PPI testing. L741,626 (water vehicle, 1, 3, or 10 mg/kg) was dissolved in 0.05-0.5% lactic acid/ water (w/v) and pH was adjusted to Z 5 using NaOH. L741,626 was administered 30 min before PRA or APO treatment.
Data analysis
PPI was defined as 100 -[(startle amplitude on prepulse trials/startle amplitude on P-ALONE trials) Â 100], and was analyzed by mixed design analyses of variance (ANOVAs). Other ANOVAs were used to assess P-ALONE magnitude, or NOSTIM trials. Post-hoc comparisons were conducted using Fisher's protected least significant difference. The magnitude of drug effects on PPI was calculated as '%PPI vehicle -%PPI drug '. Analyses of covariance were used to assess the effect of baseline PPI differences on QUIN-induced PPI effects with strain as a covariate. Regressions were based on simple linear models. Where group differences were detected in P-ALONE magnitude or baseline (vehicle) PPI, several approaches were used to parse these effects from those in PPI-drug sensitivity. Data were collapsed across prepulse intensities. Alpha was 0.05.
Results
Apomorphine effects
ANOVA of %PPI revealed significant main effects of strain [F(1,42) = 6.16, P < 0.02] and APO dose (F = 198.35, d.f. 1,42 ; P < 0.001), and a significant strain Â dose interaction (F = 39.72, d.f. 1,42; P < 0.001). Separate ANOVAs for each strain revealed significant effects of APO dose in SD rats (F = 139.05, d.f. 1,21; P < 0.001) and LE rats (F = 59.88, d.f. 1,21; P < 0.001). Importantly, the magnitude of the APO effect (%PPI vehicle -%PPI APO ) was significantly larger in SD than LE rats (P < 0.001), indicating greater sensitivity to the PPI-disruptive effects of APO in SD than LE rats ( Fig. 1a ).
On the basis of the significant main effect of strain on PPI, a separate analysis was conducted for subsets of SD and LE rats that were matched for baseline PPI levels. Subsets were constructed by eliminating the extreme responders until baseline PPI was numerically balanced between strains [mean (SEM) of vehicle PPI: SD rats: 73.0 (1.4), n = 12; LE rats: 72.2 (1.6), n = 12]. ANOVA of %PPI in these subgroups confirmed the key results: a significant strain Â dose interaction (F = 14.31, d.f. 1,22; P < 0.002), with a significantly greater APO effect (%PPI vehicle -%PPI APO ) in SD than LE rats (P < 0.002).
ANOVA of startle magnitude on P-ALONE trials revealed significant main effects of strain (F = 6.82, d.f. 1,42; P < 0.02) and APO dose (F = 8.19, d.f. 1,42; P < 0.01), and a significant strain Â dose interaction (F = 14.80, d.f. 1,42; P < 0.001). This interaction reflected significant startle-enhancing effects of APO in LE rats (F = 17.05, d.f. 1,21; P < 0.001), but not in SD rats (F < 1). Baseline (vehicle) levels of startle magnitude were almost identical across strains [mean (SEM): SD rats = 170.4 (18.9); LE rats = 176.6 (24.4)] ( Fig. 1a , inset).
To assess the impact of the startle-enhancing effects of APO on PPI strain differences, subgroups were matched as above, such that the effects of APO on startle magnitude were numerically balanced between strains [mean (SEM) startle magnitude: SD (n = 20) vehicle vs. APO = 161.8 (19.8) vs. 160.7 (30. 3); LE (n = 8) vehicle vs. APO = 237.0 (50.9) vs. 242.5 (54.1)]. ANOVA of P-ALONE amplitude revealed no significant main effect of strain (F = 2.70, d.f. 1,26; NS) or APO dose (F < 1), and no significant strain Â dose interaction (F < 1). ANOVA of %PPI in these subgroups again confirmed the key results: a significant strain Â dose interaction (F = 14.53, d.f. 1,26; P < 0.001), with a significantly greater APO effect (%PPI vehicle -%PPI APO ) in SD than LE rats (P < 0.001).
Inspection of NOSTIM levels revealed very small signal amplitudes ( < 1% of pulse alone amplitudes), yet a significant APO Â strain interaction (F = 10.85, d.f. 1,42; P < 0.01), with greater APO responsiveness in SD than LE rats. Simple regression showed that this effect contributed less than 2% of the variance to the observed APO effects on PPI in SD rats, and less than 11% in LE rats (regression weights NS).
Quinpirole effects
ANOVA of %PPI revealed no significant main effect of strain (F < 1), a significant main effect of QUIN dose (F = 54.41, d.f. 1,30; P < 0.001), and a significant strain Â dose interaction (F = 6.87, d.f. 1,30; P < 0.02). Separate ANOVAs for each strain revealed significant effects of QUIN dose in SD rats (F = 33.03, d.f. 1,15; P < 0.001) and LE rats (F = 23.24, d.f. 1,15; P < 0.001). Importantly, the magnitude of the QUIN effect (%PPI vehicle -%PPI QUIN ) was significantly larger in SD than LE rats (P < 0.02), indicating greater sensitivity to the PPI-disruptive effects of QUIN in SD than LE rats ( Fig. 1b ). Although the ANOVA detected no main effect of strain on PPI (F < 1), an analysis of covariance of the QUIN PPI effect (%PPI vehicle -%PPI QUIN ) was conducted, with baseline (vehicle) PPI as a covariate and strain as a between factor. This confirmed a significant effect of strain (F = 4.87, d.f. 1,28; P < 0.05). Thus, SD rats are more sensitive than LE rats to the PPI-disruptive effects of QUIN, even when controlling for any variance linked to levels of baseline PPI.
As Culm and Hammer (2004) demonstrated lasting effects of QUIN treatment on D2 function and PPI, we examined QUIN effects limited to the initial drug test day. ANOVA confirmed the critical findings: no significant effect of strain (F < 1), but a significant strain Â QUIN interaction (F = 5.38, d.f. 1,28; P < 0.05). Although data from this single test day did not permit calculation of a 'QUIN PPI effect', we compared PPI in QUIN-treated SD versus LE rats; this revealed a significant main effect of strain (P < 0.05), confirming that LE rats exhibited higher PPI levels after QUIN (i.e. were less inhibited by QUIN) compared with SD rats.
ANOVA of startle magnitude on P-ALONE trials revealed no significant main effect of strain (F = 2.06, d.f. 1,30; NS) or QUIN dose (F = 3.06, d.f. 1,30; 0.05 < P < 0.1), or strain Â dose interaction (F = 3.18, d.f. 1,30; 0.05 < P < 0.1). This trend toward an interaction reflected startle-reducing effects of QUIN in SD rats (F = 11.34, d.f. 1,15; P < 0.005), but not in LE rats (F < 1). Baseline (vehicle) levels of startle magnitude were almost identical across strains [mean (SEM): SD rats = 180.3 (18.9); LE rats = 178.2 (36.4)] (Fig. 1b, inset) .
To assess the impact of QUIN effects on startle magnitude on PPI strain differences, subgroups were matched as above [mean (SEM) startle magnitude: SD (n = 7) vehicle vs. QUIN = 119.4 (15.1) vs. 121.2 (24.4); LE (n = 16) vehicle vs. QUIN = 178.2 (36.4) vs. 179.0 (27.0)]. ANOVA of P-ALONE amplitude revealed no significant effect of strain (F = 2.09, d.f. 1,21; NS) or QUIN dose (F < 1), and no significant strain Â dose interaction (F < 1). ANOVA of %PPI in these subgroups confirmed a significant strain Â dose interaction (F = 6.34, d.f. 1,21; P < 0.05), with a significantly greater QUIN effect (%PPI vehicle -%PPI QUIN ) in SD than LE rats (P < 0.05).
Inspection of NOSTIM levels revealed very small signal amplitudes approximately or less than 1% of pulse alone amplitudes, yet a significant main effect of dose (F = 48.76, d.f. 1,30; P < 0.0001), but no significant effect of strain (F < 1), or strain Â dose interaction (F < 1). Simple regression showed that this effect contributed less than 7% of the variance to the observed Pramipexole effects on startle gating in rats Weber et al. 789 QUIN effects on PPI in SD rats (regression weight NS), and less than 13% in LE rats (regression weight NS).
Pramipexole effects
ANOVA of %PPI for low dose ranges (0.03-0.06 mg/kg) revealed significant main effects of strain (F = 53.59, d.f. 1,22; P < 0.001) and PRA dose (F = 11.33, d.f. 2,22; P < 0.001), but no significant strain Â dose interaction (F < 1). The magnitude of the PRA effect (%PPI vehicle -% PPI PRA ) in SD and LE rats was not significantly different for either 0.03 mg/kg (F = 1.52, d.f. 1,22; NS), or 0.06 mg/kg (F < 1). Post-hoc analysis in SD rats revealed a trend toward reduced %PPI for the lowest dose of PRA (0.03 mg/kg; 0.05 < P < 0.1) and significantly reduced %PPI for 0.06 mg/kg (P < 0.002) relative to vehicle. Post-hoc tests in LE rats revealed that %PPI was significantly reduced for 0.03 and 0.06 mg/kg doses (both P < 0.001) relative to vehicle ( Fig. 2a ).
On the basis of significant main effect of strain on percentage of PPI, a separate analysis was conducted for subsets balanced for levels of baseline PPI [mean (SEM) of vehicle PPI: SD rats: 70.7 (3.1), n = 6; LE rats: 69.1 (4.6), n = 6]. These subgroups were also similar with respect to baseline ( Fig. 2a , inset). Post-hoc tests in LE rats revealed that startle magnitude was significantly enhanced by 0.03 mg/kg (P < 0.05), but not by 0.06 mg/kg (NS).
The effects of PRA on startle magnitude were balanced across strains, as above, using values for 0.03 mg/kg PRA and vehicle [SD: vehicle = 106.4 (21.1), PRA 0.03 mg/kg . 1a) and QUIN (Fig. 1b) , SD versus LE rats did not differ in the PPI-disruptive effects of PRA. This was also true in subgroups balanced for basal PPI levels and PRA effects on startle magnitude. (b) As with the lower dose range of PRA ( Fig. 2a ), SD versus LE rats did not differ in the PPI-disruptive effects of PRA. Again, this was true in subgroups balanced for basal PPI levels. The magnitude of startle suppression in SD rats made it impossible to form subgroups balanced for PRA effects on this measure. A simple regression, however, showed that this effect did not contribute a significant proportion of variance to the observed PRA effects on PPI in any of the strains and PRA doses tested (regression weights NS). #P < 0.1, *P < 0.05, **P < 0.005, ***P < 0.0001. = 105.6 (15.7), PRA 0.06 mg/kg = 109.5 (25.0), n = 9; LE: vehicle = 197.5 (42.5), PRA 0.03 mg/kg =225.2 (21.0), PRA 0.06 mg/kg = 231.0 (40.0), n = 9]. ANOVA of P-ALONE amplitude in these rats revealed a significant effect of strain (F = 8.40, d.f. 1,16; P < 0.02), but not dose (F < 1), and no significant strain Â dose interaction (F < 1). ANOVA of %PPI in these subgroups confirmed the key results: a significant effect of strain (F = 35.79, d.f. 1,16; P < 0.0001) and dose (F = 7.80, d.f. 1,16; P < 0.002), but no significant strain Â dose interaction (F = 1.18, d.f. 1,16; NS). Importantly, the magnitude of the PRA effect (%PPI vehicle -%PPI PRA ) was not significantly greater in SD than LE rats for either 0.03 mg/kg or 0.06 mg/kg (both NS).
For the higher PRA dose range (0.1-1.0 mg/kg), ANOVA of %PPI revealed a trend toward a strain effect (F = 3.00, d.f. 1,22; 0.05 < P < 0.1), and a significant effect of dose (F = 20.80, d.f. 2,44; P < 0.0001), but no significant strain Â dose interaction (F < 1). The magnitude of the PRA effect (%PPI vehicle -%PPI PRA ) was not significantly greater in SD than LE rats for either 0.1 mg/kg (F = 1.26, d.f. 1,22; NS), or 1.0 mg/kg (F < 1) of PRA. Post-hoc analysis in SD rats revealed that %PPI was significantly reduced by 0.1 mg/kg (P < 0.005) and 1.0 mg/kg (P < 0.001) PRA relative to vehicle; in LE rats, these effects reached significance only for 1.0 mg/kg of PRA (P < 0.005) (Fig. 2b) .
On the basis of strong trend toward strain differences in PPI, subgroups were balanced for vehicle PPI levels across strains [mean (SEM) vehicle PPI: SD (n = 6), 69.4 (1.4); LE (n = 6), 68.8 (1.9)]. The subgroups were also comparable with respect to baseline (vehicle) startle magnitude [mean (SEM): SD, 201.0 (13.2); LE, 199.7 (74.2) ]. ANOVA of %PPI in these subgroups revealed a significant main effect of PRA dose (F = 11.26, d.f. 2,20 ; P < 0.001), but neither an effect of strain (F < 1), nor a strain Â dose interaction (F < 1). The magnitude of the PRA effect on PPI (%PPI vehicle -%PPI PRA ) revealed a trend toward greater PPI PRA sensitivity in LE than SD rats at 0.1 mg/kg (F = 4.44, d.f. 1,10; 0.05 < P < 0.1), but not at 1.0 mg/kg (F < 1).
ANOVA of startle magnitude on P-ALONE trials revealed a trend toward a strain effect (F = 4.07, d.f. 1,22; 0.05 < P < 0.1), a significant effect for dose (F = 4.62, d.f. 2,44 ; P < 0.02), but no strain Â dose interaction (F = 2.12, d.f. 2,44; NS) ( Fig. 2b, inset) . The magnitude of PRA-induced startle suppression in SD rats made it impossible to form subgroups balanced for PRA effects on this measure. Simple regression, however, showed that this effect contributed less than 1% of the variance to the observed PRA effect on PPI for SD versus LE rats for the highest dose of PRA (1.0 mg/kg; NS). For 0.1 mg/kg of PRA, this effect contributed to less than 8% of the observed PRA effect on PPI (NS) in LE rats, and to less than 20% in SD rats (NS).
NOSTIM levels for both low and high PRA dose range were less than 1% of pulse alone amplitudes. For low dose ranges, ANOVA revealed a trend toward a strain effect (F = 4.08, d.f. 1,22; P < 0.1), but no significant effect of dose (F < 1) or dose Â strain interaction (F = 1. 73, d.f. 2, 44; NS) . For the high dose ranges, ANOVA revealed a significant main effect of strain (F = 5.77, d.f. 1,22; P < 0.05), but not dose (F = 1.84, d.f. 2,44; NS) , and/or dose Â strain interaction (F < 1). Simple regression showed that PRA effects on NOSTIM did not contribute a significant proportion of the variance to the observed PRA effect on PPI for any of the rat strains and PRA doses (all regression weights NS). Thus, PRA effects on NOSTIM levels cannot account for the observed PRA effects on PPI.
L741,626 effects
The preferential D2 receptor antagonist L741,626 was used to assess the contributions of D2 receptor activation to the PPI-disruptive effects of APO and PRA in SD rats.
Studies first tested the effects of pretreatment with L741,626 (0, 1, 3, and 10 mg/kg) on the PPI-disruptive effects of 0.5 mg/kg APO. ANOVA revealed significant main effects of APO (F = 71.11, d.f. 1,12; P < 0.001), and L741,626 (F = 10.70, d.f. 3,12; P < 0.002), and a significant APO Â L741,626 dose interaction (F = 24.96, d.f. 3,12; P < 0.001). Post-hoc analysis revealed that APO significantly reduced %PPI in rats treated with 0 mg/kg L741,626 (P < 0.005). After APO treatment, PPI was significantly different between groups treated with 0 mg/kg L741,626 and each active dose of L741,626 [vehicle vs. 1 mg/kg (P < 0.002); vehicle vs. 3 mg/kg (P < 0.001); vehicle vs. 10 mg/kg (P < 0.001)] with greater %PPI values in rats treated with L741,626 ( Fig. 3a) .
We next tested the effects of pretreatment with L741,626 (0, 1, 3, and 10 mg/kg) on the PPI-disruptive effects of PRA (0 vs. 1 mg/kg). ANOVA of PPI revealed significant main effects of PRA (F = 15.50, d.f. 1,28; P < 0.001), and L741,626 (F = 4.56, d.f. 1,28; P < 0.02), and a significant PRA Â L741,626 dose interaction (F = 3.98, d.f. 3,28; P < 0.02). Post-hoc analysis revealed that PRA significantly disrupted PPI in rats treated with 0 mg/kg L741,626 (P < 0.005). These effects were significantly opposed by 3 mg/kg and 10 mg/kg (P < 0.02) of L741,626, but not by 1 mg/kg of L741,626 (P > 0.6) ( Fig. 3c) .
Conceivably, the ability of the lowest dose of L741,626 to prevent APO-induced but not PRA-induced PPI deficits may have reflected greater range produced by the more robust PPI-disruptive effects of this dose of APO. To assess this possibility, we repeated the experiment, using a lower dose of APO (0 vs. 0.1 mg/kg) and the critical doses of L741,626 (0 vs. 1 mg/kg). ANOVA of PPI revealed a significant main effect of APO (F = 16.42, d.f. 1,14; P < 0.002), no significant main effect of L741,626 (F = 1.86, d.f. 1,14; NS), but importantly, a significant APO Â L741,626 dose interaction (F = 16.33, d.f. 1,14; P < 0.002). APO significantly reduced %PPI in rats treated with 0 mg/kg of L741,626 (P < 0.005), and this effect was significantly opposed by 1 mg/kg L741,626 (P < 0.001) (Fig. 3b) .
Although not described above, in all studies with L741,626 versus APO or PRA, drug effects on startle magnitude (Fig. 3) and NOSTIM levels could not account for the observed patterns of PPI.
Discussion
We previously reported greater sensitivity of SD than LE rats to the PPI-disruptive effects of systemically administered DAergic agonists such as APO, amphetamine, or QUIN (Swerdlow et al., 2001b (Swerdlow et al., , 2003 (Swerdlow et al., , 2004a Weber and Swerdlow, 2008) . The strain differences in PPI-APO and PPI-QUIN sensitivity were confirmed in this study and extended by detailed analyses showing that these strain differences could not be attributed to strain differences with respect to (i) baseline (vehicle) PPI, (ii) baseline (vehicle) startle magnitude; (iii) drug effects on startle magnitude, or (iv) drug effects on NOSTIM levels.
Here, we report for the first time the PPI-disruptive effect of the preferential D3 receptor agonist, PRA. The disruption of PPI in rats by PRA confirms earlier reports with other preferential D3 agonists such as ropinirole, 7-OH-DPAT, or PD128,907 (Caine et al., 1995; Swerdlow et al., 1998; Varty and Higgins, 1998; Zhang et al., 2007) .
With the exception of the Islands of Calleja, the highest levels of D3 receptor densities have been detected in the NAC in both rodents and humans (cf. Sokoloff et al., 2006) . The disruption of PPI by PRA in two separate rat strains is, thus, consistent with a prominent role of the NAC in the regulation of PPI (Swerdlow et al., 1986; cf. Swerdlow et al., 2001a) .
Importantly, in this study, we showed for the first time that heritable strain differences in the PPI-disruptive effects of the mixed D1/D2-like agonist, APO, and the mixed D3/D2 agonist, QUIN, do not extend to the preferential D3 agonist PRA. In contrast, sensitivity to Effects of the D2 receptor antagonist L741,626 on prepulse inhibition (PPI) deficits induced by 0.5 mg/kg of apomorphine (APO) (a), 0.1 mg/kg of APO (b), or 1 mg/kg of PRA (c) and startle magnitude (insets) in Sprague-Dawley rats. (a) 0, 1, 3, and 10 mg/kg of L741,626 were tested against a standard dose of APO of 0.5 mg/kg. APO significantly reduced %PPI in rats treated with 0 mg/kg of L741,626, and this effect was significantly opposed by each active L741,626 dose. Analysis of variance (ANOVA) of startle magnitude on P-ALONE trials revealed no effect for APO, and L741,626, and no APO Â L741,626 interaction effect. (b) 0 and 1 mg/kg of L741,626 were tested against a low dose of APO (0.1 mg/kg), selected to match the magnitude of PPI disruption achieved by 1 mg/kg of pramipexole (PRA) [see (c)]. Again, APO significantly reduced PPI, and this effect was significantly opposed by 1 mg/kg L746,626. ANOVA of startle magnitude on P-ALONE trials revealed no main effect of APO, and L741,626, and no APO Â L741,626 interaction. (c) 0, 1, 3, and 10 mg/kg of L741,626 were tested against 1 mg/kg of PRA. PRA significantly disrupted percentage of PPI in rats treated with 0 mg/kg L741,626. This effect was significantly opposed by the 3 and 10 mg/kg doses of L741,626, but not by the 1 mg/kg dose (P > 0.6; Fig. 3c ). ANOVA of startle magnitude on P-ALONE trials revealed a significant main effect of PRA, reflecting reduced startle magnitude in PRA-treated rats. No effect of L741,626, and no PRA Â L741,626 interaction effect were detected. Significance levels derived from post-hoc comparisons between vehicle and dopamine (DA) agonist treatment in rats treated with 0 mg/kg L741,626 are denoted with '*' symbols. Significance levels derived from comparisons between vehicle and L741,626 pretreatment in rats treated with DA agonists are denoted with '&' symbols. **P < 0.005; & P < 0.05; && P < 0.005; &&& P < 0.0001.
the PPI-disruptive effects of PRA was comparable between SD and LE rats, and this finding persisted in careful analyses controlling for (i) baseline (vehicle) PPI, (ii) baseline (vehicle) startle magnitude; (iii) PRA effects on startle magnitude, or (iv) PRA effects on NOSTIM activity. In instances where trends were detected for strain differences in PRA sensitivity, LE rats tended to be more sensitive to the PPI-disruptive effects of PRA, compared with SD rats.
Conceivably, relatively reduced PPI in LE rats after vehicle treatment might contribute to the blunted impact of APO and QUIN on PPI, through a 'floor effect'. A floor effect, however, cannot explain the present findings, for two reasons. First, in subsets of rats matched for baseline PPI, SD rats were more sensitive to the PPI-disruptive effects of APO and QUIN. Second, greater SD sensitivity to these drug effects were confirmed by analyses of covariance used to control for sources of variance related to baseline PPI. Differential APO and QUIN sensitivities of startle magnitude might also conceivably contribute to SD versus LE difference in PPI APO and QUIN sensitivity, but the present data also do not support such an interpretation because these PPI differences were evident even among 'matched' subsets of SD and LE rats that exhibited comparable APO and QUIN effects on startle. Finally, it could be argued that differential APO and QUIN sensitivities on generalized motor activity (NOSTIM levels) may contribute to the observed strain differences with respect to the APO PPI-sensitivity. This explanation was, however, also ruled out for both drugs, based on regression analyses.
Since the discovery and cloning of the D3 receptor (Sokoloff et al., 1990) , in-vivo experiments addressing D3 receptor activation and inhibition have been hampered by several factors. First, commercially available, preferential D3 receptor ligands also have significant affinity for D2 receptors (Luedtke and Mach, 2003; Sokoloff et al., 2006) suggesting that higher doses of these compounds bind to both D3 and D2 receptors. PRA represents one of the more preferential D3 agonists, with an in-vitro D3:D2 preference of 7 : 1 (Piercey et al., 1996 , Svensson et al., 1994 relative to the high affinity state of the D2 receptor. Millan et al. (2002) have determined the D3:D2 preference of PRA to be 90 : 1 relative to the short isoform of the human receptor (D2S), and 160 : 1 relative to the long isoform (D2L). Second, D3 and D2 receptors seem to form domain-swapping heterodimers (cf. Maggio et al., 2003) . Conceivably, this leads to significant challenges of dissecting D3-mediated versus. D2-mediated effects in rats. Despite these challenges, however, recent evidence from in-vivo studies in rats suggests that PRA doses of approximately 0.1 mg/kg or less predominantly lead to D3-receptor associated effects, in the relative absence of D2-receptor associated effects (Collins et al., 2007) .
One strategy to approach these challenges is to compare the effects of drugs characterized by a range of DA receptor-subtype affinities. To determine which DA receptor subtypes contribute to the SD versus LE strain differences in PPI sensitivity, we compared drugs with prominent affinity for D1/D2-like receptors (APO), D3/D2 receptors (QUIN), and D3 receptors (PRA). Although none of the drugs are receptor specific in their binding profiles, the D3:D2 binding ratio for QUIN is approximately 10-fold lower than that for PRA (Piercey et al., 1996) . Thus, evidence for SD greater than LE PPIsensitivity for QUIN but not PRA further argues that this phenotype reflects heritable differences in the sensitivity of D2 but not D3 receptors. This view was supported by studies in which the effects of APO and PRA were tested against a dose range of the D2 receptor antagonist L741,626 in SD rats. An alternative strategy would have been to test the effects of APO and PRA against highly preferential D3 receptor antagonists such as SB-277011A and S33084, but such well-characterized D3 antagonists (reviewed in Joyce and Millan, 2005) remain difficult to obtain. L741,626 is among the most selective commercially available D2 receptor antagonists Joyce and Millan, 2005) . Nevertheless, its D2:D3 preference ratio is modest and has been estimated as 4 : 1 for native rat receptors (Cussac et al., 2003) . This suggests that at higher doses, L741,626 is likely to lose its preferential D2 inhibition and is likely to inhibit D2 and D3 receptors. In line with this, at the highest doses tested (3-10 mg/kg), L741,626 reversed PPI deficits induced by APO and by PRA. Nevertheless, the lowest dose of L741,626 had no detectable impact on PRA-induced PPI deficits, but significantly opposed the PPI-disruptive effects of both 0.1 and 0.5 mg/kg APO. The lower APO dose was selected to disrupt PPI by an amount comparable with that produced by PRA. Thus, under conditions of 'matched PPI deficits', a low dose of L741,626 fully reversed APO-induced PPI deficits, whereas PRA-induced PPI deficits were completely unaffected. These data argue against a major involvement of D2 receptor activation in the induction of PRA-induced PPI deficits, and by extension, suggest that the PPI-disruption induced by PRA is predominantly because of D3 activation. In addition, L741,626 has substantially higher binding ratios for D2 than for D1 (approximately 200), D4 (approximately 80), or D5 (approximately 160) receptors . Although we cannot exclude that cooperation between D2 receptors and these other receptor subtypes may occur, these data indicate that the prevention of APO-induced PPI deficits by the low dose of L741,626 is unlikely because of blockade of D1, D4, or D5 receptors, independent of its antagonism of D2 receptors.
Even though PRA displays preferential binding to D3 receptors relative to all other receptor types, it is not possible to entirely exclude an involvement of a small number of other receptor types in PPI deficits induced by PRA, including the D4 receptor, and perhaps the a 2B adrenergic and 5-HT1 A serotonergic receptors. First, the in-vitro binding ratio of PRA to D3 versus D4 receptors has been approximated as 12 : 1 (Millan et al., 2002) or 17 : 1 (Piercey et al., 1996) . This indicates that D4 receptor activation may play some role after treatment with the highest PRA doses tested. Nevertheless, it would be difficult to attribute the lack of SD greater than LE sensitivity to disruption of PPI by PRA to a major D4 receptor involvement for the lower PRA doses tested. Second, Millan et al. (2002) reported relatively low preferential binding rates in the range of 60 : 1 for PRA to the D3 receptor relative to the a 2B and 5-HT1 A receptors. In contrast, Piercey et al. (1996) reported values of greater than 200 : 1 for a 2 and greater than 1000 for 5-HT1 A receptors. Again, if anything, this may indicate an involvement of these receptor types in PPI deficits induced by the highest doses of PRA, but less likely so for the lowest doses of PRA tested. For all other receptors tested, including DA D1 and D5, preferential binding ratios to the D3 receptor have been assessed as 150 : 1 or greater by both studies (Millan et al., 2002; Piercey et al., 1996) . Nevertheless, it is important to acknowledge that none of these pharmacological tools have absolute receptor specificity, and behavioral responses to these drugs cannot be attributed with certainty to any single receptor or receptor subtype. Perhaps the most conservative conclusion is that based on the convergent evidence from the present studies: the D2 receptor does not seem to play a prominent role in the PPI-disruptive effects of PRA; by extension, the heritable differences in sensitivity to the PPI-disruptive effects of D2 stimulation are not manifested in a differential sensitivity to PRA.
Our earlier studies have determined that the SD versus LE differences in PPI 'disruptability' by DA agonists reflects processes localized within the NAC , associated with NAC DA-stimulated GTPgS binding , CREB phosphorylation , suppression of c-fos expression (Saint Marie et al., 2006) , and specific patterns of gene activation (Shilling et al., 2008) . The present findings suggest that the heritable behavioral phenotype reflects differential sensitivity of D2 but not D3 receptors. These findings further suggest the testable hypothesis that the D2 and D3 regulations of PPI are mediated through mechanisms that differ at the levels of NAC DA-linked signal transduction and the genes associated with this process.
